Eli Lilly to collaborate with Germany's CureVac on cancer vaccines

(Reuters) - U.S. drugmaker Eli Lilly and Co said on Wednesday it will collaborate with CureVac AG on development of up to five immunotherapy cancer vaccines using the German company's messenger RNA (mRNA) technology.